3 results
Primary Objective * To evaluate the effect of a 6-week treatment with elafibranor versus placebo on hepatic lipid composition in subjects with a fatty liver.Secondary objectives * To evaluate the between treatment difference (elafibranor 120 mg/d vs…
Primary objectives * surrogate endpoint (at interim analysis)To evaluate the efficacy of elafibranor QD for 72 weeks versus placebo on resolution of NASH without worsening of fibrosis.* Resolution of NASH is defined as the disappearance of…
Primary objectives:- to explore transfusion induced differences in vital (activity) parameters such as heart rate, respiratory rate and activity before and after RBC transfusions in regularly transfused patients using the pinpointIQ* system.- To…